Your browser doesn't support javascript.

Biblioteca Virtual en Salud

Hipertensión

Home > Búsqueda > ()
XML
Imprimir Exportar

Formato de exportación:

Exportar

Email
Adicionar mas contactos
| |

Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy / Journal of the Korean Cancer Association, 대한암학회지

Min-Kyoon KIM; Wonshik HAN; Hyeong-Gon MOON; Soo-Kyung AHN; Jisun KIM; Jun-Woo LEE; Ju-Yeon KIM; Taeryung KIM; Kyung-Hun LEE; Tae-Yong KIM; Sae-Won HAN; Seock-Ah IM; Tae-You KIM; In-Ae PARK; Dong-Young NOH.
Artículo en Inglés | WPRIM | ID: wpr-198396

PURPOSE:

The ability to accurately predict the likelihood of achieving breast conservation surgery (BCS) after neoadjuvant chemotherapy (NCT) is important in deciding whether NCT or surgery should be the first-line treatment in patients with operable breast cancers. MATERIALS AND

METHODS:

We reviewed the data of 513 women, who had stage II or III breast cancer and received NCT and surgery from a single institution. The ability of various clinicopathologic factors to predict the achievement of BCS and tumor size reduction to < or = 3 cm was assessed. Nomograms were built and validated in an independent cohort.

RESULTS:

BCS was performed in 50.1% of patients, with 42.2% of tumors reduced to < or = 3 cm after NCT. A multivariate logistic regression analysis showed that smaller initial tumor size, longer distance between the lesion and the nipple, absence of suspicious calcifications on mammography, and a single tumor were associated with BCS rather than mastectomy (p < 0.05). Negative estrogen receptor, smaller initial tumor size, higher Ki-67 level, and absence of in situ component were associated with residual tumor size < or = 3 cm (p < 0.05). Two nomograms were developed using these factors. The areas under the receiver operating characteristic curves for nomograms predicting BCS and residual tumor < or = 3 cm were 0.800 and 0.777, respectively. The calibration plots showed good agreement between the predicted and actual probabilities.

CONCLUSION:

We have established a model with novel factors that predicts BCS and residual tumor size after NCT. This model can help in making treatment decisions for patients who are candidates for NCT.
Biblioteca responsable: WPRO